<DOC>
	<DOCNO>NCT01656018</DOCNO>
	<brief_summary>The purpose study evaluate safety , acceptability , pharmacokinetics ( body medication ) , ex vivo ( test outside body ) pharmacodynamics ( medication body ) TMC278 long act ( slowly effective initial dosage maintain effect long period time ) administer intramuscular ( ie , muscle ) injection adult participant seronegative human immunodeficiency virus type 1 ( HIV-1 ) .</brief_summary>
	<brief_title>A Study Evaluate Safety , Acceptability , Pharmacokinetics , ex Vivo Pharmacodynamics TMC278 Long Acting Formulation HIV-1 Seronegative Participants</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multi-arm ( one treatment group ) , dose-ranging study ( clinical study different dos study medication test ) evaluate safety , acceptability , pharmacokinetics , ex vivo pharmacodynamics single multiple intramuscular injection long act TMC278 human immunodeficiency virus type 1 ( HIV-1 ) seronegative ( negative serum reaction ) male female participant . The study consist 3 phase include screen phase , treatment phase , follow phase ( approximately 4 6 month first dose study medication ) . In treatment phase , enrol participant divide 2 arm , ie , Arm A ( female participant ) divide Arm 1A , Arm 2A , Arm 3A , Arm 4A , Arm 5A 12 female participant per arm ; Arm B ( male participant ) divide Arm 1B , Arm 2B , Arm 3B , Arm 4B , Arm 5B 6 male participant per arm . Safety evaluation include assessment adverse event , clinical laboratory test , electrocardiogram , physical examination , vital sign monitor throughout study . The total duration study participant approximately 5 7 month .</detailed_description>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>Human immunodeficiency virus type 1 ( HIV1 ) seronegative screen enrollment Not pregnant breastfeeding female Agrees protocoldefined method contraception Abstinence insertion anything rectum ( eg , medication , enema , penis , sex toy ) 72 hour 72 hour rectal biopsy visit Abstinence insertion anything vagina ( eg , tampon , medication , douche , penis , sex toy ) 72 hour 72 hour cervical vaginal biopsy visit Postexposure prophylaxis HIV exposure within 6 month prior screen know HIVinfected partner Use systemic immunomodulatory medication within 4 week prior enrollment Use vaginally rectally administer medication product ( include condom ) contain Nonoxynol9 ( N9 ) within 4 week prior enrollment Abnormalities cervical , vaginal , colorectal mucosa , significant symptom ( ) , opinion clinician represent contraindication protocolrequired biopsy History recurrent urticaria History electrocardiogram demonstrate prolonged QT interval History significant gastrointestinal bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>TMC278</keyword>
	<keyword>Human Immunodeficiency Virus Type 1</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Ex-vivo pharmacodynamics</keyword>
</DOC>